Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities

Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. J Am Med Assoc. 2022;327:464–77.

Article  CAS  Google Scholar 

Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606.

Article  PubMed  PubMed Central  Google Scholar 

Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9:3.

Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801–8.

Article  PubMed  Google Scholar 

Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.

Article  PubMed  PubMed Central  Google Scholar 

Surveillance. Epidemiology, and End Results (SEER) Program Populations (1969-2020). National Cancer Institute, DCCPS, Surveillance Research Program; 2023. www.seer.cancer.gov/popdata.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transpl. 2019;54:353–67.

Article  CAS  Google Scholar 

Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017;6:2876–85.

Article  PubMed  PubMed Central  Google Scholar 

Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123:3141–9.

Article  CAS  PubMed  Google Scholar 

Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012;158:91–8.

Article  PubMed  Google Scholar 

Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, et al. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities. Cancer. 2018;124:1710–21.

Article  PubMed  Google Scholar 

Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3:2986–94.

Article  PubMed  PubMed Central  Google Scholar 

Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020;10:80.

Article  PubMed  PubMed Central  Google Scholar 

Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017;123:1590–6.

Article  PubMed  Google Scholar 

Bhutani M, Blue BJ, Cole C, Badros AZ, Usmani SZ, Nooka AK, et al. Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer J. 2023;13:189.

Article  PubMed  PubMed Central  Google Scholar 

Ailawadhi S, Bhatia K, Aulakh S, Meghji Z, Chanan-Khan A. Equal treatment and outcomes for everyone with multiple myeloma: are we there yet? Curr Hematol Malig Rep. 2017;12:309–16.

Article  PubMed  Google Scholar 

Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, et al. Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care. JCO Oncol Pract. 2020;16:e341–e9.

Article  PubMed  Google Scholar 

Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282–7.

Article  PubMed  PubMed Central  Google Scholar 

Maignan K, Fashoyin-Aje LA, Torres AZ, Fernandes LL, Gwise T, Baxi SB, et al. Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data. Blood Cancer J. 2022;12:65.

Article  PubMed  PubMed Central  Google Scholar 

Baker A, Braggio E, Jacobus S, Jung S, Larson D, Therneau T, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013;121:3147–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peres LC, Oswald LB, Dillard C, De Avila G, Nishihori T, Blue BJ, et al. Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy. Blood. 2022;140:623–5.

Article  Google Scholar 

Pulte D, Redaniel MT, Brenner H, Jansen L, Jeffreys M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014;55:1083–9.

Article  PubMed  Google Scholar 

Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, et al. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020;126:5077–87.

Article  PubMed  Google Scholar 

McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic status and access to healthcare: interrelated drivers for healthy aging. Front Public Health. 2020;8:231.

Article  PubMed  PubMed Central  Google Scholar 

Care Without Coverage: Too Little, Too Late. Washington (DC): National Academic Press (US); 2002.

Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, et al. Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol. 2023;98:41–8.

Article  PubMed  Google Scholar 

Doucette K, Taylor AO, Chan B, Ma X, Ahn J, Vesole DH, et al. Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis. Ann Hematol. 2023;102:1443–58.

Article  PubMed  Google Scholar 

Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89:825–30.

Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif